Last reviewed · How we verify
NCT03879837
Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg
Phase 3 trial testing Fluticasone propionate pressurized metered dose inhaler in Asthma in 1,902 participants. Completed in 9 July 2021.
28 May 2021
Quick facts
| Lead sponsor | Actavis Inc. |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 1,902 |
| Start date | 25 March 2019 |
| Primary completion | 28 May 2021 |
| Estimated completion | 9 July 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fluticasone propionate pressurized metered dose inhaler — full drug profile →
- Flovent HFA pressurized metered dose inhaler — full drug profile →
- Placebo pressurized metered dose inhaler — full drug profile →
Conditions studied
- Asthma — all drugs for Asthma →
Sponsor
Actavis Inc. — full company profile →
Who can join
Adults 18 to 75, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in Adult Subjects with Asthma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03879837
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Asthma
Currently open trials in the same condition.
- NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
- NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
- NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
- NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
- NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting
Other Actavis Inc. trials
Trials by the same sponsor.
- NCT03954444 — A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream" · Phase 3 · completed
- NCT03756883 — Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With · Phase 3 · completed
- NCT03499873 — Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension · Phase 3 · completed
- NCT03301649 — Clinical Endpoint Study of Ivermectin 0.5% Lotion · Phase 3 · completed
- NCT02495168 — Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03879837 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Actavis Inc.
- Last refreshed: 1 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03879837.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing